NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 0.9500
-0.0130 (-1.35%)
Oct 13, 2026, 1:53 PM CET
NextCell Pharma AB Market Cap
NextCell Pharma AB has a market cap or net worth of 120.07 million as of October 12, 2026. It is the 40,506th most valuable company in the world and the 580th biggest in Sweden. Its market cap has increased by 16.03% in one year.
Market Cap
120.07M
Enterprise Value
98.98M
Revenue
10.78M
Global Rank
Country Rank
#580 Sweden
PE Ratio
n/a
ChartMarket Cap Chart
Since July 13, 2017, NextCell Pharma AB's market cap has increased from 33.03M to 120.07M, an increase of 263.57%. That is a compound annual growth rate of 14.96%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 13, 2026 | 120.07M | 47.46% |
| Dec 30, 2025 | 81.43M | -60.77% |
| Dec 30, 2024 | 207.58M | 129.58% |
| Dec 29, 2023 | 90.42M | -62.64% |
| Dec 30, 2022 | 242.03M | -9.28% |
| Dec 30, 2021 | 266.79M | -35.76% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Jul 13, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Elicera Therapeutics AB | 183.86M |
| Xintela AB | 154.60M |
| Diamyd Medical AB | 151.88M |
| Simris Group AB (PUBL) | 150.50M |
| Abera Bioscience AB | 140.62M |
| Initiator Pharma | 123.22M |
| OncoZenge AB | 115.37M |
| Ascelia Pharma AB | 114.84M |